Radiotherapy for metastatic bone disease: current standards and future prospectus

References

• Lubitz JD, Riley GF. Trends in Medicare payments in the last year of life. N. Engl. J. Med.328, 1092–1096 (1993).
   PubMed Web of Science ®Google Scholar
• Janjan N, Lutz S, Bedwinek J et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology appropriateness criteria expert panel on radiation oncology. J. Palliat. Med.12, 417–423 (2009).
   PubMed Web of Science ®Google Scholar
• Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management. Eur. J. Cancer36, 476–482 (2000).
   PubMed Web of Science ®Google Scholar
• Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer58, 178–182 (1986).
   PubMed Web of Science ®Google Scholar
• Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. Am. J. Med.81, 381–386 (1986).
   PubMed Web of Science ®Google Scholar
• Knudson G, Grinis G, Lopez-Majano V et al. Bone scan as a stratification variable in advanced prostate cancer. Cancer68, 316–320 (1991).
   PubMedGoogle Scholar
• Lai PP, Perez CA, Lockett MA. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.24, 423–430 (1992).
   PubMedGoogle Scholar
• Yamashita K, Denno K, Ueda T et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer71, 1297–1302 (1993).
   PubMed Web of Science ®Google Scholar
• Coia L, Hanks G, Martz K et al. Practice patterns of palliative care for the United States 1984–1985. Int. J. Radiat. Oncol. Biol. Phys.14, 1261–1269 (1988).
   PubMedGoogle Scholar
• Lutz S, Chow E, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer109, 1462–1470 (2007).
   PubMed Web of Science ®Google Scholar
• Chow E, Harris K, Fan G et al. Palliative radiotherapy trials for bone metastases: a systematic review. J. Clin. Oncol.25, 1423–1436 (2007).
   PubMed Web of Science ®Google Scholar
• Hoskin P, Stratford M, Folkes L et al. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet355, 1428–1429 (2000).
   PubMed Web of Science ®Google Scholar
• Chow E, Wu J, Hoskin P et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother. Oncol.64, 275–280 (2002).
   PubMed Web of Science ®Google Scholar
• Hadi S, Zhang L, Hird A et al. Validation of symptom clusters in patients with metastatic bone pain. Curr. Oncol.15, 211–218 (2008).
   PubMedGoogle Scholar
• Chow E, Hird A, Velikova G et al. The European Organisation for Research and Treatment of Cancer quality of life questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur. J. Cancer45, 1146–1152 (2009).
   PubMed Web of Science ®Google Scholar
• Madsen E. Painful bone metastasis: efficacy of radiotherapy assessed by the patients: a randomized trial comparing 4 Gy 6 versus 10 Gy 2. Int. J. Radiat. Oncol. Biol. Phys.9, 1775–1779 (1983).
   PubMed Web of Science ®Google Scholar
• Price P, Hoskin P, Easton D et al. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother. Oncol.6, 247–255 (1986).
   PubMed Web of Science ®Google Scholar
• Hirokawa Y, Wadasaki K, Kashiwado K et al. A multiinstitutional prospective randomized study of radiation therapy of bone metastases. Nippon Igaku Hoshasen Gakkai Zasshi48, 1425–1431 (1988).
   PubMedGoogle Scholar
• Okawa T, Kita M, Goto M et al. Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases. Radiother. Oncol.13, 99–104 (1988).
   PubMed Web of Science ®Google Scholar
• Cole D. A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin. Oncol.1, 59–62 (1989).
   PubMedGoogle Scholar
• Kagei K, Suzuki K, Shirato H et al. A randomized trial of single and multifraction radiation therapy for bone metastases: a preliminary report. Gan. No. Rinsho.36, 2553–2558 (1990).
   PubMedGoogle Scholar
• Hoskin P, Price P, Eason D et al. A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother. Oncol.23, 74–78 (1992).
   PubMed Web of Science ®Google Scholar
• Rasmussen B, Vejborg I, Jensen A et al. Irradiation of bone metastases in breast cancer patients: a randomized study with one year follow-up. Radiother. Oncol.34, 179–184 (1995).
   PubMedGoogle Scholar
• Niewald M, Tkocz H, Abel U et al. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int. J. Radiat. Oncol. Biol. Phys.36, 1085–1089 (1996).
   PubMedGoogle Scholar
• Gaze M, Kelly C, Kerr G et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomized trial of two fractionation schedules. Radiother. Oncol.45, 109–116 (1997).
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int. J. Radiat. Oncol. Biol. Phys.42, 161–167 (1998).
   PubMedGoogle Scholar
• Foro P, Algara M, Reig A et al. Randomized prospective trial comparing three schedules of palliative radiotherapy. Preliminary results. Oncologia21, 55–60 (1998).
   Google Scholar
• Nielsen O, Bentzen S, Sandberg E et al. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother. Oncol.47, 233–240 (1998).
   PubMed Web of Science ®Google Scholar
• Koswig S, Budach V. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 3 Gy vs. 1 Gy). A prospective study [German]. Strahlenther. Onkol.175, 500–508 (1999).
   PubMed Web of Science ®Google Scholar
• Steenland E, Leer J, van Houwelingen et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis study. Radiother. Oncol.52, 101–109 (1999).
   PubMed Web of Science ®Google Scholar
• Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with a multifraction schedule over 12 months of patient follow-up. Radiother. Oncol.52, 111–121 (1999).
   PubMed Web of Science ®Google Scholar
• Ozsaran Z, Yalman D, Anacak Y et al. Palliative radiotherapy in bone metastases: results of a randomized trial comparing three fractionation schedules. J. Balkan. Union Oncol.6, 43–48 (2001).
   Google Scholar
• Sarkar SK, Sarkar S, Pahari B et al. Multiple and single fraction palliative radiotherapy in bone secondaries: a prospective study. Ind. J. Radiol. Imag.12, 281–284 (2002).
   Google Scholar
• Altundag M, Ucer A, Calikoglu T et al. Single (500 cGy, 800 cGy) and multifraction (300 10 cGy) radiotherapy schedules in the treatment of painful bone metastases. Turk. J. Hematol. Oncol.12, 16–21 (2002).
   Google Scholar
• Badzio A, Senkus-Konefka E, Jereczek-Fossa B et al. 20Gy in five fractions versus 8 Gy in one fraction in palliative radiotherapy of bone metastases: a multicentre randomized study. J. Oncol.53, 261–264 (2003).
   Google Scholar
• van der Linden Y, Lok J, Steenland E et al. Single fraction radiotherapy is efficacious: A further analysis of the Dutch Bone Metastasis study controlling for the influence of retreatment. Int. J. Radiat. Oncol. Biol. Phys.59, 528–537 (2004).
   PubMed Web of Science ®Google Scholar
• Hartsell W, Konski A, Scott C et al. Randomized trial of short versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst.97, 798–804 (2005).
   PubMedGoogle Scholar
• Kaasa S, Brenne E, Lund J-A et al. Prospective randomized multicentre trial on single fraction radiotherapy (8Gy 1) versus multiple fractions (3Gy – 10) in the treatment of painful bone metastases. Radiother. Oncol.79, 278–284 (2006).
   PubMed Web of Science ®Google Scholar
• Sze W, Shelley M, Held I et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy: a systematic review of randomized trials. Clin. Oncol.15, 345–352 (2003).
   PubMed Web of Science ®Google Scholar
• Foro A, Fontanals A, Galceran J et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother. Oncol.89, 150–155 (2008).
   PubMedGoogle Scholar
• Sande T, Ruenes R, Lund J et al. Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial. Radiother. Oncol.91, 261–266 (2009).
   PubMed Web of Science ®Google Scholar
• Wu JS, Wong R, Johnston M et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int. J. Radiat. Oncol. Biol. Phys.55, 594–605 (2003).
   PubMed Web of Science ®Google Scholar
• van den Hout W, van der Linden Y, Steenland E et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost–utility analysis based on a randomized trial. J. Natl Cancer Inst.95, 222–229 (2003).
   PubMedGoogle Scholar
• Macklis R, Cornelli H, Lasher J. Brief courses of palliative radiotherapy for metastatic bone pain: a pilot cost-minimization comparison with narcotic analgesics. Am. J. Clin. Oncol.21, 617–622 (1998).
   PubMedGoogle Scholar
• Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.60, 1373–1378 (2004).
   PubMed Web of Science ®Google Scholar
• Fairchild A, Barnes E, Ghosh S et al. International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice? Int. J. Radiat. Oncol. Biol. Phys.75, 1281–1628 (2009).
   Google Scholar
• Chow E. A Phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. Clin. Oncol.18, 125–128 (2006).
   PubMed Web of Science ®Google Scholar
• Chow E, Ling A, Davis L et al. Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother. Oncol.75, 64–69 (2005).
   PubMedGoogle Scholar
• Chang EL, Shiu AS, Mendel E et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J. Neurosurg. Spine7, 151–160 (2007).
   PubMed Web of Science ®Google Scholar
• Sahgal A, Ma L, Gibbs I et al. Spinal cord tolerance for stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. DOI: 10.1016/j.ijrobp.2009.05.023 (2009) (Epub ahead of print).
   Google Scholar
• Sahgal A, Larson D, Chang E. Stereotactic body radiosurgery for spinal metastases: a critical review. Int. J. Radiat. Oncol. Biol. Phys.71, 652–655 (2008).
   PubMed Web of Science ®Google Scholar
• Rose PS, Laufer I, Boland PJ et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J. Clin. Oncol.27, 5075–5079 (2009).
   PubMed Web of Science ®Google Scholar
• Gomez DR, Hunt MA, Jackson A et al. Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy. Radiother. Oncol.93, 414–418 (2009).
   PubMedGoogle Scholar
• Tsai JT, Lin JW, Chiu WT et al. Assessment of image-guided CyberKnife® radiosurgery for metastatic spine tumors. J. Neurooncol.94, 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• Sahgal A, Ames C, Chou D et al. Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int. J. Radiat. Oncol. Biol. Phys.74, 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Bilsky MH, Lovelock DM et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int. J. Radiat. Oncol. Biol. Phys.71, 484–490 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson JW, Yoo DS, Sampson JH et al. Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. Int. J. Radiat. Oncol. Biol. Phys.73, 1369–1375 (2008).
   PubMedGoogle Scholar
• Gerszten PC, Burton SA, Ozhasoglu C et al. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine32, 193–199 (2007).
   PubMed Web of Science ®Google Scholar
• Ryu S, Rock J, Rosenblum M et al. Patterns of failure after single-dose radiosurgery for spinal metastasis. J. Neurosurg.101(Suppl. 3), 402–405 (2004).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Lovelock DM, Yenice KM et al. Multifractionated image-guided and stereotactic intensity-modulated radiotherapy of paraspinal tumors: a preliminary report. Int. J. Radiat. Oncol. Biol. Phys.62, 53–61 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton AJ, Lulu BA, Fosmire H et al. Preliminary clinical experience with linear accelerator-based spinal stereotactic radiosurgery. Neurosurgery36, 311–319 (1995).
   PubMed Web of Science ®Google Scholar
• Nguyen QN, Shiu AS, Rhines LD et al. Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.76(4), 1185–1192 (2010).
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Mason M, Parmar M et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol.10, 872–876 (2009).
   PubMed Web of Science ®Google Scholar
• Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther.4, 92–100 (2007).
   PubMedGoogle Scholar
• Vassiliou V, Kalogeropoulou C, Christopoulos C et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int. J. Radiat. Oncol. Biol. Phys.67, 254–272 (2007).
   Google Scholar
• Vassiliou V, Kalogeropoulou C, Giannopoulou E et al. A novel study investigating the therapeutic outcome of patients with lytic, mixed, and sclerotic bone metastases treated with combined radiotherapy and ibandronate. Clin. Exp. Metastasis24, 169–178 (2007).
   PubMedGoogle Scholar
• Manas A, Casas F, Ciria J et al. Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases. Clin. Transl. Oncol.10, 281–287 (2008).
   PubMedGoogle Scholar
• Vassiliou V, Leotsinides M, Kalogeropoulou C et al. Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer. BJU Int.104, 417–418 (2009).
   PubMedGoogle Scholar
• Atahan L, Yildiz F, Cengiz M et al. Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a Phase IV randomized clinical study. Support Care Cancer DOI: 10.1007/s00520-009-0663-x (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Diel I, Bergner R, Grotz K. Adverse effects of bisphosphonates: current issues. J. Support Oncol.5, 475–482 (2007).
   PubMedGoogle Scholar
• Ward W, Holsenbeck S, Dorey F et al. Metastatic disease of the femur: surgical treatment. Clin. Orthop. Relat. Res.415(Suppl.), S230–S244 (2003).
   Google Scholar
• Ristevski B, Jenkinson R, Stephen D et al. Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome. Can. J. Surg.52, 302–308 (2009).
   PubMed Web of Science ®Google Scholar
• Sarahrudi K, Wolf H, Funovics P et al. Surgical treatment of pathological fractures of the shaft of the humerus. J. Trauma66, 789–794 (2009).
   PubMedGoogle Scholar
• Bilsky M, Laufer I, Burch S. Shifting paradigms in the treatment of metastatic spine disease. Spine34, S202–S107 (2009).
   Google Scholar
• Patchell R, Tibbs P, Regine W et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet366, 643–648 (2005).
   PubMed Web of Science ®Google Scholar
• Marazano E, Trippa F, Casale M et al. 8 Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a Phase III randomized multicentre Italian trial. Radiother. Oncol.93, 174–179 (2009).
   PubMedGoogle Scholar
• Maranzano E et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a Phase III, randomized, multicenter trial. J. Clin. Oncol.223, 3358–3365 (2005).
   Google Scholar
• Rades D et al. A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. Cancer101, 2687–2692 (2004).
   PubMed Web of Science ®Google Scholar
• Halpin R, Bendok B, Liu J. Minimally invasive treatments for spinal metastases: vertebroplasty, kyphoplasty, and radiofrequency ablation. J. Support Oncol.2, 339–351 (2004).
   PubMedGoogle Scholar
• Alvarez L, Perez-Higuerez A, Quinones D et al. Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life. Eur. Spine J.12, 356–360 (2003).
   PubMedGoogle Scholar
• Anselmetti G, Zoarski G, Manca A et al. Percutaneous vertebroplasty and bone cement leakage: clinical experience with a new high-viscosity bone cement and delivery system for vertebral augmentation in benign and malignant compression fractures. Cardiovasc. Intervent. Radiol.31, 937–947 (2008).
   PubMed Web of Science ®Google Scholar
• Ramos L, de las Heras J, Sanchez S et al. Medium-term results of percutaneous vertebroplasty in multiple myeloma. Eur. J. Haematol.77, 7–13 (2006).
   PubMedGoogle Scholar
• Cahana A, Seium Y, Dilby M et al. Percutaneous vertebroplasty in octogenarians: results and follow-up. Pain Pract.4, 316–323 (2005).
   Google Scholar
• Pflugmacher R, Taylor R, Agarwal A et al. Balloon kyphoplasty in the treatment of metastatic disease of the spine: a 2-year prospective evaluation. Eur. Spine J.17, 1042–1048 (2008).
   PubMedGoogle Scholar
• Khanna A, Reinhardt M, Togawa D et al. Functional outcomes of kyphoplasty for the treatment of osteoporotic and osteolytic vertebral compression fractures. Osteoporos. Int.17, 817–826 (2006).
   PubMedGoogle Scholar
• Gerszten P, Germanwala A, Burton S et al. Combination kyphoplasty and spinal radiosurgery: a new treatment paradigm for pathological fractures. J. Neurosurg. Spine3, 296–301 (2005).
   PubMed Web of Science ®Google Scholar
• Jang J, Lee S. Efficacy of percutaneous vertebroplasty combined with radiotherapy in osteolytic metastatic spinal tumors. J. Neurosurg. Spine2, 243–248 (2005).
   PubMedGoogle Scholar
• Gerszten P, Monaco E 3rd. Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique. Neurosurg. Focus27, E9 (2009).
   PubMed Web of Science ®Google Scholar
• Hoskin P. Radioisotopes for metastatic bone pain. Lancet Oncol.6, 353–354 (2005).
   PubMedGoogle Scholar
• Oosterhof G, Roberts J, de Reijke T et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a Phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur. Urol.44, 519–526 (2003).
   PubMed Web of Science ®Google Scholar
• Smeland S, Erikstein B, Aas M et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int. J. Radiat. Oncol. Biol. Phys.56, 805–813 (2003).
   Google Scholar
• Baczyk M, Czepczynski R, Milecki P et al. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl. Med. Commun.28, 245–250 (2007).
   PubMedGoogle Scholar
• Cardoso E, Ashamalla H, Weng L et al. Percutaneous tumor curettage and interstitial delivery of samarium-153 coupled with kyphoplasty for treatment of vertebral metastases. J. Neurosurg. Spine10, 336–342 (2009).
   PubMedGoogle Scholar
• Storto G, Klain M, Paone G et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone39, 35–41 (2006).
   PubMedGoogle Scholar
• Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled Phase II study. Lancet Oncol.8, 587–594 (2007).
   PubMed Web of Science ®Google Scholar
• Bashir F, Parry J, Windsor P. Use of a modified hemi-body irradiation technique for metastatic carcinoma of the prostate: report of a 10-year experience. Clin. Oncol.20, 591–598 (2008).
   Web of Science ®Google Scholar
• Berg R, Yilmaz M, Hoyer M et al. Half body irradiation of patients with multiple bone metastases: a Phase II trial. Acta Oncol.48, 556–561 (2009).
   PubMed Web of Science ®Google Scholar
• Connor S, Pyenson B, Fitch K et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J. Pain Symptom Manage.33, 238–246 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor D, Ostermann J, Van Houtven C et al. What length of hospice use maximizes reduction in medical expenditures near death in the U.S. Medicare program? Soc. Sci. Med.65, 1466–1478 (2007).
   PubMed Web of Science ®Google Scholar
• McCloskey S, Tao M, Rose C et al. National survey of perspectives of palliative radiation therapy: role, barriers, and needs. Cancer J.13, 130–137 (2007).
   PubMedGoogle Scholar
• Lutz S, Spence C, Chow E et al. Survey on use of palliative radiotherapy in hospice care. J. Clin. Oncol.22, 3581–3586 (2004).
   PubMedGoogle Scholar
• Lutz S, Lupu D, Johnstone P et al. The influence of the newly formed hospice and palliative medicine subspecialty on radiation oncology and end-of-life care. J. Am. Coll. Radiol.5, 1102–1105 (2008).
   PubMedGoogle Scholar
• Lutz S, Fairchild A, Chow et al. Background, rationale and goals for the 2010 International Consensus Conference bone metastasis treatment workshop. Clin. Oncol.21, 649–651 (2009).
   Google Scholar